These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 19995961)
1. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Gastaminza P; Whitten-Bauer C; Chisari FV Proc Natl Acad Sci U S A; 2010 Jan; 107(1):291-6. PubMed ID: 19995961 [TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208 [TBL] [Abstract][Full Text] [Related]
3. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets. Suzuki T Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994 [TBL] [Abstract][Full Text] [Related]
4. New perspectives in HCV therapy: entry inhibitors. Donia M; Cacopardo B; Libra M; Scalia G; McCubrey JA; Nicoletti F Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):181-94. PubMed ID: 20497122 [TBL] [Abstract][Full Text] [Related]
5. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881 [TBL] [Abstract][Full Text] [Related]
6. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617 [TBL] [Abstract][Full Text] [Related]
8. Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Yu X; Sainz B; Petukhov PA; Uprichard SL Antimicrob Agents Chemother; 2012 Dec; 56(12):6109-20. PubMed ID: 22948883 [TBL] [Abstract][Full Text] [Related]
9. The hepatitis C virus life cycle as a target for new antiviral therapies. Pawlotsky JM; Chevaliez S; McHutchison JG Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890 [TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle. Park SB; Boyer A; Hu Z; Le D; Liang TJ Antivir Ther; 2019; 24(5):371-381. PubMed ID: 30880685 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of compound activity against hepatitis C virus in replicon systems. Yang G; Huang M Curr Protoc Pharmacol; 2010 Sep; Chapter 13():Unit 13B.1. PubMed ID: 22294366 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of Pycnogenol® on hepatitis C virus replication. Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333 [TBL] [Abstract][Full Text] [Related]
13. Evaluation systems for anti-HCV drugs. Moriishi K; Matsuura Y Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275 [TBL] [Abstract][Full Text] [Related]
14. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Hu Z; Hu X; He S; Yim HJ; Xiao J; Swaroop M; Tanega C; Zhang YQ; Yi G; Kao CC; Marugan J; Ferrer M; Zheng W; Southall N; Liang TJ Antiviral Res; 2015 Dec; 124():20-9. PubMed ID: 26515788 [TBL] [Abstract][Full Text] [Related]
15. A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. Cannalire R; Barreca ML; Manfroni G; Cecchetti V J Med Chem; 2016 Jan; 59(1):16-41. PubMed ID: 26241789 [TBL] [Abstract][Full Text] [Related]
16. Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression. Nguyen BN; Okuno Y; Ajiro M; Iida K; Denawa M; Yamamoto M; Sakamoto N; Kagechika H; Hagiwara M J Med Virol; 2017 Jul; 89(7):1224-1234. PubMed ID: 27922182 [TBL] [Abstract][Full Text] [Related]
17. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase. Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598 [TBL] [Abstract][Full Text] [Related]
18. Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression. Lin CK; Tseng CK; Liaw CC; Huang CY; Wei CK; Sheu JH; Lee JC Sci Rep; 2018 Jun; 8(1):8676. PubMed ID: 29875371 [TBL] [Abstract][Full Text] [Related]
19. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Chockalingam K; Simeon RL; Rice CM; Chen Z Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3764-9. PubMed ID: 20142494 [TBL] [Abstract][Full Text] [Related]
20. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. Guedj J; Neumann AU J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]